In the UK, the Royal College of Psychiatrists, in association with the Royal College of General Practitioners, has embarked upon a Defeat Depression campaign, with the aim of increasing the knowledge of health care professionals in the recognition and effective treatment of depressive illness and to enhance public awareness of the nature, course and treatment of depressive disorders.
Depression is one of the most common psychiatric disorders, affecting up to 10% of the population. Around 5%-6% of the population will be suffering from major depression at any one time. In one year, says the campaign management committee, general practitioners will record the diagnosis of depression in 3% of the population, and it is probable that a similar number of depressed patients will go unrecognised.
Only 10% of depressed patients are referred to a psychiatrist for treatment, and only 1% require hospitalization, said Andre Tylee of the department of general practice at St George's Hospital Medical School, London. Depression is therefore a disorder mostly encountered by GPs, he said, adding that unfortunately as many as 50% of cases may be missed. While a further 10% are subsequently recognized, 40% receive no treatment and either remit spontaneously, continue with episodic illness or go on to develop a chronic depressive disorder.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze